Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $3.17 Million - $4.78 Million
175,000 Added 38.46%
630,000 $14.3 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $3.91 Million - $5.87 Million
230,000 Added 102.22%
455,000 $8.54 Million
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $6.25 Million - $9.71 Million
-475,000 Reduced 67.86%
225,000 $4.19 Million
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $1.45 Million - $2.15 Million
100,000 Added 16.67%
700,000 $12.6 Million
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $505,999 - $900,250
-25,000 Reduced 4.0%
600,000 $12.4 Million
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $8.24 Million - $10.2 Million
275,000 Added 78.57%
625,000 $19.3 Million
Q3 2020

Nov 16, 2020

SELL
$35.98 - $47.66 $1.8 Million - $2.38 Million
-50,000 Reduced 12.5%
350,000 $12.9 Million
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $1.58 Million - $2.37 Million
35,000 Added 9.59%
400,000 $18 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $1.3 Million - $2.61 Million
-35,000 Reduced 8.75%
365,000 $26.2 Million
Q3 2019

Nov 14, 2019

SELL
$39.36 - $76.8 $2.95 Million - $5.76 Million
-75,000 Reduced 15.79%
400,000 $15.7 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $7.91 Million - $12.3 Million
150,000 Added 46.15%
475,000 $37.1 Million
Q1 2019

May 15, 2019

SELL
$27.39 - $68.41 $825,753 - $2.06 Million
-30,148 Reduced 8.49%
325,000 $19.4 Million
Q4 2018

Feb 14, 2019

BUY
$22.8 - $33.93 $483,360 - $719,316
21,200 Added 6.35%
355,148 $10.2 Million
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $432,386 - $626,124
-14,534 Reduced 4.17%
333,948 $12.2 Million
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $3.29 Million - $5.99 Million
150,000 Added 75.57%
348,482 $13.2 Million
Q1 2018

May 15, 2018

BUY
$17.1 - $26.61 $1.71 Million - $2.66 Million
100,000 Added 101.54%
198,482 $4.66 Million
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $932,624 - $1.93 Million
98,482
98,482 $1.93 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.